Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
26.3 USD +1.98% Intraday chart for Mirum Pharmaceuticals, Inc. +8.63% -10.91%
May. 31 Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC MT
May. 31 Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
BU
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be presented at EASL Congress
AQ
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
BU
Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting
AQ
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
BU
Mirum Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
BU
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
BU
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
BU
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals LIVMARLI Receives Positive Reimbursement Recommendation by Canada s CADTH for Patients with Cholestatic Pruritusin Alagille Syndrome
AQ
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
BU
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
BU
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
Mirum Pharmaceuticals - Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI
AQ
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. News Mirum Pharmaceuticals, Inc.
  5. Press Releases